What Doctor to See if Baby Brain Affected by Brethine

Neurotoxicol Teratol. Writer manuscript; available in PMC 2014 Mar ane.

Published in final edited form equally:

PMCID: PMC3492522

NIHMSID: NIHMS395217

TERBUTALINE IMPAIRS THE Evolution OF PERIPHERAL NORADRENERGIC PROJECTIONS: IMPLICATIONS FOR AUTISM SPECTRUM DISORDERS AND PHARMACOTHERAPY OF PRETERM LABOR

Abstruse

Terbutaline, a β_ii-adrenoceptor agonist, is used off-label for long-term management of preterm labor; such use is associated with increased risk of neurodevelopmental disorders, including autism spectrum disorders. We explored the mechanisms underlying terbutaline'due south furnishings on evolution of peripheral sympathetic projections in developing rats. Terbutaline administration on postnatal days 2–5 led to firsthand and persistent deficiencies in cardiac norepinephrine levels, with greater effects in males than in females. The liver showed a lesser effect; we reasoned that the tissue differences could represent participation of retrograde trophic signaling from the postsynaptic site to the developing neuronal projection, since hepatic β_ii-adrenoceptors decline in the perinatal catamenia. Appropriately, when nosotros gave terbutaline before, on gestational days 17–20, nosotros saw the same deficiencies in hepatic norepinephrine that had been seen in the centre with the later assistants paradigm. Administration of isoproterenol, which stimulates both β₁- and β₂-subtypes, also had trophic effects that differed in direction and disquisitional flow from those elicited by terbutaline; methoxamine, which stimulates α_ane-adrenoceptors, was without outcome. Thus, terbutaline, operating through trophic interactions with β₂-adrenoceptors, impairs development of noradrenergic projections in a manner similar to that previously reported for its effects on the same neurotransmitter systems in the immature cerebellum. Our results point to the likelihood of autonomic dysfunction in individuals exposed prenatally to terbutaline; in light of the connectedness between terbutaline and autism, these results could also contribute to autonomic dysregulation seen in children with this disorder.

Keywords: Autism, β-Adrenergic agonists, Norepinephrine, Preterm commitment, Sympathetic nervous system, Terbutaline

INTRODUCTION

Information technology is abundantly clear that "classic" neurotransmitters, such as norepinephrine, serotonin and acetylcholine, act equally morphogens to direct the assembly of the mammalian encephalon (Bruel-Jungerman et al., 2011; Lauder, 1985; Whitaker-Azmitia, 1991), a function that likely evolved from their roles in invertebrate embryogenesis (Buznikov et al., 1996, 2007). Although less well studied, similar processes operate for development of peripheral innervation; in the sympathetic nervous system, for example, the development of cholinergic neurotransmission at the ganglion dictates the differentiation, neurotransmitter subtype and outgrowth of postganglionic neurons (Azevedo and Osswald, 1986; Blackness, 1980; Blackness et al., 1976). These types of neurotrophic relationships underlie the vulnerability of the immature nervous system to "misprogramming" resulting from exposure to neuroactive chemicals, leading ultimately to neurodevelopmental disorders (Grandjean and Landrigan, 2006; Lauder, 1985; Whitaker-Azmitia, 1991).

Considerable attention has been paid to the part of illicit drugs, and pesticides or other environmental neurotoxicants, simply the potential impact of therapeutic agents has been less well explored. Recent attending has turned to the effects of β-adrenergic agonists and their use in the management of preterm labor, asthma and fetal heart block (Cheslack-Postava et al., 2007; Connors, 2008; Connors et al., 2005; Hadders-Algra et al., 1986; Kilburn et al., 2009; Pitzer et al., 2001; Robinson et al., 2001; Witter et al., 2009). Clinical and epidemiological studies show an increased take chances of learning disabilities and autism spectrum disorders (ASD) resulting from utilize of these agents in pregnancy (Connors, 2008; Connors et al., 2005; Croen et al., 2011; Hadders-Algra et al., 1986; Kilburn et al., 2009; Pitzer et al., 2001; Robinson et al., 2001; Witter et al., 2009), and animal models signal that such exposures lead to structural, neurochemical and behavioral damage (Feenstra, 1992; Garofolo et al., 2003; Rhodes et al., 2004; Slotkin et al., 2003; Witter et al., 2009; Zerrate et al., 2007). In office, this occurs considering developing cells do non display β-adrenoceptor desensitization in response to backlog stimulation, and instead actually show enhanced responsiveness (Slotkin et al., 2003; Slotkin and Seidler, 2006). Accordingly, receptor overstimulation leads to a positive feedback that further augments the cellular response to continued or subsequent stimulation, ultimately culminating in altered cell differentiation or fifty-fifty prison cell death (Connors, 2008; Fu et al., 2004; Yan et al., 2000). Such furnishings are particularly of import considering terbutaline, a β_ii-selective agonist, is still used "off characterization" for maintenance command of preterm labor (Goldenberg, 2002), however its ineffectiveness for that purpose (Thornton, 2005), and despite the fact that the U.S. Nutrient and Drug Administration specifically warns against its employ (U.S. Food and Drug Administration, 2011). Prolonged terbutaline administration in the second to third trimester is associated with significantly increased incidence of ASD (Connors, 2008; Connors et al., 2005; Kilburn et al., 2009; Witter et al., 2009; Zerrate et al., 2007), a take chances that is probable to be fifty-fifty greater in individuals with β-adrenoceptor polymorphisms that impair desensitization (Cheslack-Postava et al., 2007; Connors et al., 2005).

In our previous work, terbutaline administered to newborn rats on postnatal (PN) days 2–5, neurodevelopmentally equivalent to late second trimester man development, evoked structural, functional and behavioral anomalies (Garofolo et al., 2003; Rhodes et al., 2004; Slotkin et al., 1989, 1990; Zerrate et al., 2007). Some of the most notable changes were in the cerebellum and further, the structural alterations and design of neuroinflammation resembled those seen in postmortem samples of children and adults with ASD (Connors, 2008; Rhodes et al., 2004; Zerrate et al., 2007). At the neurotransmitter level, terbutaline appears to disrupt noradrenergic circuits in detail, reducing cerebellar synaptogenesis for this transmitter (Slotkin et al., 1989), while at the same enhancing the expression of both α_one- and α_two-adrenoceptors (Kreider et al., 2004; Slotkin et al., 1990); again, this likely reflects overstimulation that preempts the normal neurotrophic part of norepinephrine (Sanders et al., 2011). The question remains as to whether the furnishings of terbutaline reflect a specific role involving cerebellar noradrenergic projections (i.e. regional specification), or whether there is more widespread vulnerability of noradrenergic neurons that depends instead on a specific stage of neuronal differentiation. In the newborn rat, the window for the peak of cerebellar development corresponds too to the period in which peripheral noradrenergic projections develop (Rodier, 1988; Slotkin, 1986). This presents us with the opportunity to distinguish between the two possible mechanisms. If it is specifically the cerebellum that is targeted, then peripheral noradrenergic projections will non be affected similarly, but if it is a critical period of neurodifferentiation that is responsible for the defects, then the effects volition exist like for sympathetic neuronal development. In the current study, we evaluated the effects of terbutaline (β_two-agonist) on development of cardiac and hepatic noradrenergic innervation in contrast to the furnishings of isoproterenol (β₁- and β₂-agonist) and methoxamine (α₁-agonist) during different developmental periods. We found evidence that β_ii-adrenoceptor stimulation during a critical developmental period leads to deficiencies in peripheral sympathetic noradrenergic innervation, providing a link to observations of autonomic dysfunction reported in ASD (Anderson et al., 2012; Fan et al., 2009; Witter et al., 2009).

METHODS

Animal treatments

All procedures utilized tissues that were archived from earlier studies and maintained frozen at −45° C, then that no additional animals were actually used for this study. Details of fauna husbandry, institutional approvals, maternal and litter characteristics, and growth curves, have all been presented in earlier work from the original beast cohorts (Garofolo et al., 2003; Kreider et al., 2004; Slotkin et al., 1996; Thai et al., 1996). Timed-pregnant Sprague-Dawley rats were housed individually and given free access to food and water. For studies of gestational terbutaline handling, dams received daily subcutaneous injections of 10 mg/kg terbutaline sulfate (Sigma Chemic Co., St. Louis, MO) by s.c. injection on gestational days (GD) 17–xx, whereas controls received equivalent volumes (1 ml/kg) of isotonic saline vehicle. Postnatal treatments were conducted similarly with daily s.c. injections to the pups on PN2–v, PN21–24 (i.e. immediately after weaning) or for 4 sequent days in adulthood (males only, trunk weight 250–300 one thousand); treatment groups comprised 10 mg/kg terbutaline sulfate, ane.25 mg/kg l-isoproterenol HCl (Sigma) or ten mg/kg methoxamine (Sigma), each with corresponding saline command groups. The PN21–24 and adult grouping were included to show that the effects seen with prenatal or early postnatal exposures were developmental, that is, they occur just with treatment in a critical window. Tissue samples were obtained 24 hour subsequently the last injection, and additionally on PN60 for the accomplice given terbutaline given on PN2–five. All groups comprised no more than than one male and one female from a given litter.

The doses used in this study were selected so equally to produce prolonged stimulation of the corresponding adrenergic receptors in heart and liver (β₂ for terbutaline, β₁ and β₂ for isoproterenol, α₁ for methoxamine), equally evidenced by effects on tissue growth, receptor concentrations and receptor-mediated signal transduction (Garofolo et al., 2003; Kreider et al., 2004; Slotkin et al., 1996; Thai et al., 1996). It would be inappropriate to lucifer the dose in newborn rats to terbutaline given to pregnant women because terbutaline is metabolized much more quickly in rats (Tegner et al., 1984); the drug is given to humans by continuous infusion or repeated oral dosing so every bit to maintain round-the-clock receptor stimulation (Lam et al., 2001), and we selected doses that, given one time daily, accomplish the aforementioned biologic result in rats. For terbutaline, the treatment produces prolonged adenylyl cyclase activation, β_two-receptor downregulation (Auman et al., 2001a, b), metabolic activation (Kudlacz et al., 1989; Morris and Slotkin, 1985), and brain neuroinflammation and structural changes resembling findings in ASD (Rhodes et al., 2004; Zerrate et al., 2007). The isoproterenol treatment elicits sustained, maximal elevation of center rate (Hou et al., 1989b; Hou and Slotkin, 1989; Seidler and Slotkin, 1979) and metabolic activation in both heart (Bareis and Slotkin, 1978; Bartolome et al., 1977) and liver (Bartolome et al., 1985; Slotkin et al., 1986). The methoxamine regimen produces stimulation sufficient to downregulate α₁-receptors (Thai et al., 1996).

Assays and data analysis

Tissues were thawed on ice and deproteinized by homogenization in 0.one N perchloric acid containing 3,4-dihydroxybenzylamine (Sigma) every bit an internal standard. Homogenates were sedimented at 26,000 × one thousand for ten minutes, the supernatant solutions were decanted, and norepinephrine was then trace-enriched by alumina adsorption, separated by contrary-phase loftier performance liquid chromatography and quantitated by electrochemical detection (Seidler and Slotkin, 1981); values were corrected for recovery of the internal standard. Preliminary studies verified that measured norepinephrine levels were stable even afterwards prolonged tissue storage at −45° C.

Data are presented equally means and standard errors, with handling differences established by ANOVA utilizing the factors of handling, tissue, sex and age. Post-hoc tests for individual treatment effects were established with Fisher'southward Protected Least Significant Difference Test. Significance was assumed at p < 0.05. Because each treatment image involved a separate cohort of animals, treatment comparisons were made only to the matched control group from the aforementioned cohort.

RESULTS

Every bit establish in our earlier studies with these treatments, terbutaline given on GD17–20 had no upshot on the number of fetuses and produced trivial or no change fetal body weight, middle weight of liver weight (Auman et al., 2001a; Slotkin et al., 2001), nor were any changes seen for the postnatal terbutaline regimens (Auman et al., 2001b; Slotkin et al., 2001). At all ages tested, neither isoproterenol nor methoxamine had any meaning effects on body weights (Thai et al., 1996); liver weights were inside v% of normal, and were unchanged relative to body weight (Thai et al., 1996). Nonetheless, isoproterenol produced significant cardiac hypertrophy when given on PN21–24 or in adulthood, but not earlier (Giannuzzi et al., 1995).

Terbutaline administration on PN2–five elicited pregnant deficits in peripheral norepinephrine levels that were sexual activity- and tissue-selective (Fig. ane). In males, cardiac norepinephrine showed pregnant decrements on PN6, persisting into young adulthood (PN60). In the liver, there was no initial arrears but values were subnormal on PN60; although this event was individually nonsignificant, it was likewise indistinguishable from the significant deficit seen in the heart at the same age, and a comparing of treatment effects across the two tissues showed a significant principal consequence of terbutaline (p < 0.03) without a treatment × tissue interaction.

Effects of terbutaline given on PN2–5 on norepinephrine levels in heart and liver (note different scales). Data correspond means and standard errors obtained from eight–10 animals in each grouping for each historic period and sex activity. ANOVA appears at the pinnacle of the panel; lower-order tests for males and females were carried out considering of the treatment interaction with sex, and these appear within the panel. For males, values were separated past tissue because of the treatment × tissue interaction. For the heart, there was no interaction of treatment × age, so but main treatment effects are reported, whereas tests at each age were carried out for the liver (meaning treatment × age interaction) merely were not significant; even so, the decrement in both the center and liver on PN60 were pregnant taken together (p < 0.03 for the primary treatment effect, no interaction of handling × tissue). No lower social club tests were carried out for females because of the absence of significance for the overall ANOVA. NS = not pregnant.

In our earlier work with terbutaline, we found that hepatic β-adrenoceptor downregulation was much larger than for the heart with either gestational or postnatal handling (Auman et al., 2001a, b), reflecting the predominance of the β₂-subtype in the liver as compared to the β_i-subtype in the heart; also, dissimilar the middle, hepatic β_two-receptors decline sharply after nascence (McMillian et al., 1983). Accordingly, we explored whether the lack of immediate effect (PN6) on liver norepinephrine levels reflected an earlier critical period. Terbutaline given prenatally on GD17–20 elicited a large decrement in liver norepinephrine concentrations measured on GD21 (Fig. 2A), whereas the same treatment given postnatally on PN2–five did non (Fig. 2B). Since terbutaline is a β₂-selective agonist, we then investigated whether the relative insensitivity in the postnatal period was shared past the response to isoproterenol, which stimulates both the β_one- and β_two-subtypes; isoproterenol given on PN2–5 elicited a pregnant increment in hepatic norepinephrine (Fig. 2B). This effect besides showed a critical period, since similar treatment on PN21–24 failed to show an increase and really produced a significant decrease (Fig. 2C); when given in adulthood, there was no effect of isoproterenol (Fig. 2d). We as well examined the consequences of α_ane-adrenergic receptor stimulation with methoxamine over the same developmental menstruum in which the response to isoproterenol changed and disappeared. Methoxamine given on PN21–24 (Fig. 2C) or in adulthood (Fig. 2d) did not cause statistically significant changes in norepinephrine levels.

Effects of adrenergic agonists on liver norepinephrine levels. The indicated agents were given for four days preceding the age at which evaluations were carried out, shown at the tiptop of each panel: (A) terbutaline given on GD17–xx, evaluated on GD21 (n=xiv); (B) terbutaline or isoproterenol given on PN2–v, evaluated on PN6 (control north=23, terbutaline n=17, isoproterenol n=6; (C) isoproterenol or methoxamine given on PN21–24, evaluated on PN25 (command n=11, isoproterenol n=12, methoxamine n=17); (D) isoproterenol or methoxamine given for 4 days in adulthood, evaluated on the fifth day (control due north=12, isoproterenol n=17, methoxamine due north=eight). Values are shown without separation by sexual practice: (A) sex was not adamant in the fetuses; (B) and (C) there was no interaction of treatment × sex; (D) subjects were males just. ANOVA appears at the summit of each panel and asterisks denote private groups that differ from the corresponding command. Note different scales for each panel. NS = non significant.

DISCUSSION

Our results testify that terbutaline impairs peripheral sympathetic neuronal development when exposure occurs during the aforementioned critical menstruum in which it targets development of cerebellar noradrenergic projections, and farther, that these effects are not shared by agonists that operate through adrenergic receptor subtypes other than the β₂-adrenoceptor. The findings support a specific trophic role for the β_two-adrenoceptor in neuronal development involving not merely the central nervous arrangement merely likewise peripheral sympathetic projections.

Administration of terbutaline on PN2–5 elicited firsthand and long-lasting deficits in cardiac norepinephrine levels, with the upshot restricted to males. This parallels our earlier work showing greater adverse cerebellar effects of the aforementioned treatment in males (Rhodes et al., 2004). Notably, terbutaline given during this menstruum also produces persistent β-adrenoceptor downregulation (Slotkin et al., 2005), which would further augment the functional consequences of deficient presynaptic norepinephrine levels. Interestingly, though, the effects were less notable in the liver, despite the fact that there are no substantial neurochemical disparities between these noradrenergic projections and those that innervate the heart; indeed, both pathways develop with a virtually identical time grade (Slotkin et al., 1995). What is different, though, is the postsynaptic receptor population in the 2 tissues. The neonatal center possesses high concentrations of β₁-receptors and α₁-receptors which are maintained into adulthood (Slotkin et al., 1995). In the liver, however, the predominant β-receptor subtype is the β₂-adrenoceptor, which is extremely loftier in the fetus and newborn whereas α₁-receptors are depression (McMillian et al., 1983; Slotkin et al., 1995). Hepatic β₂-adrenoceptors and then pass up and are replaced by the α₁-subtype, which then assumes the same metabolic function (gluconeogenesis) previously controlled by β₂-receptors (Exton, 1979; Katz et al., 1985; McMillian et al., 1983). If postsynaptic receptor populations are responsible for the difference in terbutaline'southward effects on cardiac vs. hepatic noradrenergic projections, then it would imply that there is a retrograde point from the end-organ that contributes to the development of these neurons. There is prior evidence for retrograde control of sympathetic neuronal development based on studies of cease-organ removal (Dibner et al., 1977), but to our knowledge no ane has looked at whether specific neurotransmitter receptors could trigger retrograde trophic signaling. Appropriately nosotros focused on treatments targeting dissimilar receptor populations and different disquisitional periods for their effects on hepatic norepinephrine.

Since hepatic β₂-adrenoceptors turn down sharply in the perinatal period (McMillian et al., 1983), we reasoned that terbutaline treatment earlier than PN2–5 might elicit a response more than alike to that seen in the center. This prediction was verified: when we administered terbutaline on GD17–twenty, we saw deficits in hepatic norepinephrine that paralleled the effect that had been seen in the heart with the later administration paradigm. We then explored whether other adrenergic receptor subtypes exerted similar trophic furnishings on hepatic noradrenergic projections. Administration of isoproterenol, which targets both β_one- and β₂-adrenoceptors, produced upregulation when given on PN2–5, the opposite effect from that obtained with terbutaline in the heart with the aforementioned regimen, or in the liver with the earlier regimen. It is thus evident that the β₁-adrenoceptor too exerts trophic control over development of hepatic noradrenergic projections but in a management opposite to that of the β_two-receptor. There is ample precedent for these divergent trophic actions, since the two subtypes can accept opposite effects on signaling pathways mediating apoptosis (Chesley et al., 2000; Shizukuda and Buttrick, 2002; Zaugg et al., 2000). The β₁-dependent trophic component too displayed a critical period, since isoproterenol administration on PN21–25 decreased norepinephrine instead of increasing it; administration in adulthood had no impact, reinforcing the concept that these are indeed developmental effects. Finally, we examined the effects of methoxamine (α₁-adrenoceptor agonist), administered during the period in which hepatic α_one-adrenoceptors spike (McMillian et al., 1983) or in adulthood. There was no effect, reinforcing the unique trophic roles of β-adrenoceptors as distinct from the α₁-subtype. It should be noted that the methoxamine regimen was sufficient to cause persistent overstimulation of the α₁-receptors, as evidenced past downregulation of this receptor subtype (Thai et al., 1996), and so the lack of outcome on presynaptic norepinephrine did not reflect assistants of a subeffective dose.

In the present written report, we pursued the elapsing of the synaptic defects elicited by terbutaline in only one model (treatment on PN2–5) and found that the upshot lasted into young adulthood. Nevertheless, persistence is not required to produce lasting defects in sympathetic part. The perinatal stage is a disquisitional catamenia in which presynaptic stimulation of postsynaptic targets is required for proper evolution of end-organ part, then that early on deficiencies result in permanently subnormal responses (Hou et al., 1989a, b; Hou and Slotkin, 1989; Navarro et al., 1991; Slotkin et al., 2003). Appropriately, after-emerging changes in receptor expression and tissue function are credible after terbutaline exposure on GD17–20 or PN2–5 only non with exposure on PN11–14 (Slotkin et al., 2005).

In summary, our results point to a specific trophic role for β-adrenoceptors modulating the development of peripheral noradrenergic projections, likely through retrograde signaling via postsynaptic receptors located in the target tissues. This function is not shared by the α₁-subtype. The results are of clinical relevance for two specific reasons. Start, terbutaline is widely used in the long-term management of preterm labor, so that tens of thousands of newborns are exposed to this handling each yr in the U.S. alone (Goldenberg, 2002). Although there has been considerable work on increased risk of neurodevelopmental disorders resulting from such exposure (Cheslack-Postava et al., 2007; Connors, 2008; Connors et al., 2005; Hadders-Algra et al., 1986; Kilburn et al., 2009; Pitzer et al., 2001; Robinson et al., 2001; Witter et al., 2009), our results indicate to the likelihood of autonomic consequences besides, including cardiovascular and metabolic dysfunction. The second betoken is the potential relationship to ASD. Prolonged prenatal terbutaline exposure increases the risk of ASD, especially in association with β₂-adrenoceptor polymorphisms that enhance responsiveness (Cheslack-Postava et al., 2007; Connors, 2008; Connors et al., 2005; Witter et al., 2009), and some of our morphological findings for cerebellar development parallel those in ASD (Rhodes et al., 2004; Vargas et al., 2004; Zerrate et al., 2007). ASD is also associated with autonomic dysfunction (Anderson et al., 2012; Fan et al., 2009; Witter et al., 2009) and there is a subset of ASD patients who prove specific defects in sympathetic activation (Hirstein et al., 2001). The nowadays piece of work shows that terbutaline exposure during the relevant developmental period for its utilise in preterm labor, impairs evolution of peripheral sympathetic projections, with the same sex activity selectivity found for the incidence of ASD (male > female person). Our earlier piece of work detailed adverse effects of terbutaline on expression of postsynaptic adrenergic and cholinergic receptors in these same target tissues (Auman et al., 2001a, b; Slotkin et al., 2005), properties that would amplify presynaptic defects; and indeed, we identified parallel changes in both cardiac and hepatic office in response to sympathetic and parasympathetic stimuli (Auman et al., 2001a; Hou and Slotkin, 1989; Navarro et al., 1991; Slotkin et al., 2005). The present results are therefore relevant for outcomes of inappropriate terbutaline use in preterm labor, specifically pointing to the need to examine whether exposed children show autonomic dysfunction, as well as providing a contributory component to autonomic manifestations in ASD (Anderson et al., 2012; Fan et al., 2009; Hirstein et al., 2001; Witter et al., 2009).

​

Highlights

• Prenatal terbutaline exposure is associated with increased incidence of autism

• Developing rats given terbutaline showed scarce peripheral noradrenergic development

• Vulnerability depended on the concentration of β_two-adrenoceptors in the target organs

• Effects were not shared by stimulants acting at β_one- or α₁-adrenoceptors

• Dumb noradrenergic development could contribute to autonomic dysfunction in autism or in offspring of women given terbutaline for preterm labor

Acknowledgments

Enquiry support was provided by NIH ES10356.

Abbreviations

ANOVA	assay of variance
ASD	Autism Spectrum Disorders
GD	gestational solar day
PN	postnatal day

Footnotes

Disclaimers: TAS has provided expert witness testimony in the by iii years at the behest of the post-obit law firms: The Calwell Practice (Charleston WV), Finnegan Henderson Farabow Garrett & Dunner (Washington DC), Carter Police force (Peoria IL), Gutglass Erickson Bonville & Larson (Madison WI), The Killino Firm (Philadelphia PA), Alexander Hawes (San Jose, CA), Pardieck Law (Seymour, IN), Tummel & Casso (Edinburg, TX) and the Shanahan Police force Group (Raleigh NC).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that employ to the journal pertain.

References

• Anderson CJ, Colombo J, Unruh KE. Educatee and salivary indicators of autonomic dysfunction in autism spectrum disorder. Dev, Psychobiol. 2012 doi: 10.1002/dev.21051. [PMC complimentary commodity] [PubMed] [CrossRef] [Google Scholar]
• Auman JT, Seidler FJ, Slotkin TA. Regulation of fetal cardiac and hepatic β-adrenoceptors and adenylyl cyclase signaling: terbutaline furnishings. Am J Physiol. 2001a;281:R1079–R89. [PubMed] [Google Scholar]
• Auman JT, Seidler FJ, Tate CA, Slotkin TA. β-Adrenoceptor-mediated cell signaling in the neonatal heart and liver: responses to terbutaline. Am J Physiol. 2001b;281:R1895–R901. [PubMed] [Google Scholar]
• Azevedo I, Osswald West. Trophic role of the sympathetic innervation. J Pharmacol. 1986;17:30–43. [PubMed] [Google Scholar]
• Bareis DL, Slotkin TA. Responses of heart ornithine decarboxylase and adrenal catecholamines to methadone and sympathetic stimulants in developing and adult rats. J Pharmacol Exp Ther. 1978;205:164–74. [PubMed] [Google Scholar]
• Bartolome J, Grignolo A, Bartolome Thousand, Trepanier P, Lerea L, Weigel S, et al. Postnatal methyl mercury exposure: effects on ontogeny of renal and hepatic ornithine decarboxylase responses to trophic stimuli. Toxicol Appl Pharmacol. 1985;80:147–54. [PubMed] [Google Scholar]
• Bartolome J, Lau C, Slotkin TA. Ornithine decarboxylase in developing rat heart and brain: function of sympathetic development for responses to autonomic stimulants and the effects of reserpine on maturation. J Pharmacol Exp Ther. 1977;202:510–8. [PubMed] [Google Scholar]
• Black IB. Developmental regulation of neurotransmitter phenotype. Curr Topics Dev Biol. 1980;fifteen:27–40. [PubMed] [Google Scholar]
• Black IB, Flower EM, Hamill RW. Central regulation of sympathetic neuron evolution. Proc Natl Acad Sci United states of america. 1976;73:3575–8. [PMC free article] [PubMed] [Google Scholar]
• Bruel-Jungerman Eastward, Lucassen PJ, Francis F. Cholinergic influences on cortical development and adult neurogenesis. Behav Encephalon Res. 2011;221:379–88. [PubMed] [Google Scholar]
• Buznikov GA, Nikitina LA, Bezuglov VV, Francisco ME, Obispo-Peak IN, Peterson RA, et al. New perspectives on roles for neurotransmitters in early (" pre-nervous ") embryogenesis. In: Ruždijić Southward, Rakić L, editors. Neurobiological Studies — from Genes to Behaviour. Kerala, Republic of india: Signpost/Transworld Research Network; 2007. pp. 183–96. [Google Scholar]
• Buznikov GA, Shmukler YB, Lauder JM. From oocyte to neuron: practice neurotransmitters part in the same mode throughout development? Prison cell Mol Neurobiol. 1996;xvi:532–59. [PubMed] [Google Scholar]
• Cheslack-Postava K, Fallin Md, Avramopoulos D, Connors SL, Zimmerman AW, Eberhart CG, et al. β2-Adrenergic receptor gene variants and take chances for autism in the AGRE cohort. Mol Psychiat. 2007;12:283–91. [PubMed] [Google Scholar]
• Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani Due south, Lakatta EG, et al. The β₂-adrenergic receptor delivers an antiapoptotic indicate to cardiac myocytes through K_i-dependent coupling to phosphatidylinositol 3′-kinase. Circ Res. 2000;87:1172–9. [PubMed] [Google Scholar]
• Connors SL. Prenatal β₂-adrenergic receptor signaling and autism: dysmaturation and retained fetal role. In: Zimmerman AW, editor. Autism: Current Theories and Evidence. Totowa NJ: Humana Printing; 2008. pp. 147–82. [Google Scholar]
• Connors SL, Crowell DE, Eberhart CG, Copeland J, Newschaffer CJ, Spence SJ, et al. β₂-Adrenergic receptor activation and genetic polymorphisms in autism: data from dizygotic twins. J Kid Neurol. 2005;20:876–84. [PubMed] [Google Scholar]
• Croen LA, Connors SL, Matevia M, Qian Y, Newschaffer C, Zimmerman AW. Prenatal exposure to β_two-adrenergic receptor agonists and risk of autism spectrum disorders. J Neurodev Disord. 2011;3:307–15. [PMC free article] [PubMed] [Google Scholar]
• Dibner Medico, Mytilineou C, Black IB. Target organ regulation of sympathetic neuron evolution. Brain Res. 1977;123:301–x. [PubMed] [Google Scholar]
• Exton JH. Mechanisms involved in α-adrenergic furnishings of catecholamines on liver metabolism. J Cyclic Nucleotide Res. 1979;5:277–87. [PubMed] [Google Scholar]
• Fan X, Miles JH, Takahashi N, Yao G. Aberrant transient pupillary calorie-free reflex in individuals with autism spectrum disorders. J Autism Dev Disord. 2009;39:1499–508. [PubMed] [Google Scholar]
• Feenstra MGP. Functional neuroteratology of drugs interim on adrenergic receptors. Neurotoxicology. 1992;13:55–63. [PubMed] [Google Scholar]
• Fu YC, Chi CS, Yin SC, Hwang B, Chiu YT, Hsu SL. Norepinephrine induces apoptosis in neonatal rat endothelial cells via downward-regulation of Bcl-2 and activation of beta-adrenergic and caspase-2 pathways. Cardiovasc Res. 2004;61:143–51. [PubMed] [Google Scholar]
• Garofolo MC, Seidler FJ, Cousins MM, Tate CA, Qiao D, Slotkin TA. Developmental toxicity of terbutaline: critical periods for sex activity-selective effects on macromolecules and DNA synthesis in rat encephalon, heart, and liver. Brain Res Bull. 2003;59:319–29. [PubMed] [Google Scholar]
• Giannuzzi CE, Seidler FJ, Slotkin TA. β-Adrenoceptor control of cardiac adenylyl cyclase during development: agonist pretreatment in the neonate uniquely causes heterologous sensitization, non desensitization. Encephalon Res. 1995;694:271–8. [PubMed] [Google Scholar]
• Goldenberg RL. The management of preterm labor. Obstetrics and Gynecology. 2002;100:1020–37. [PubMed] [Google Scholar]
• Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. Lancet. 2006;368:2167–78. [PubMed] [Google Scholar]
• Hadders-Algra Thousand, Touwen BC, Huisjes HJ. Long-term follow-up of children prenatally exposed to ritodrine. Br J Obstet Gynæcol. 1986;93:156–61. [PubMed] [Google Scholar]
• Hirstein W, Iversen P, Ramachandran VS. Autonomic responses of autistic children to people and objects. Proc R Soc Lond B. 2001;268:1883–8. [PMC free article] [PubMed] [Google Scholar]
• Hou Q-C, Baker FE, Seidler FJ, Bartolome Chiliad, Bartolome J, Slotkin TA. Role of sympathetic neurons in development of β-adrenergic control of ornithine decarboxylase activity in peripheral tissues: effects of neonatal half-dozen-hydroxydopamine treatment. J Dev Physiol. 1989a;xi:139–46. [PubMed] [Google Scholar]
• Hou Q-C, Seidler FJ, Slotkin TA. Development of the linkage of β-adrenergic receptors to cardiac hypertrophy and middle charge per unit command: neonatal sympathectomy with 6-hydroxydopamine. J Dev Physiol. 1989b;11:305–11. [PubMed] [Google Scholar]
• Hou Q-C, Slotkin TA. Effects of prenatal dexamethasone or terbutaline exposure on evolution of neural and intrinsic command of heart rate. Pediatr Res. 1989;26:554–7. [PubMed] [Google Scholar]
• Katz MS, Boland SR, Schmidt SJ. Developmental changes of β-adrenergic receptor-linked adenylate cyclase of rat liver. Am J Physiol. 1985;248:E712–E8. [PubMed] [Google Scholar]
• Kilburn KH, Thrasher JD, Immers NB. Do terbutaline- and mold-associated impairments of the brain and lung chronicle to autism? Toxicol Industr Wellness. 2009;25:703–10. [PubMed] [Google Scholar]
• Kreider ML, Seidler FJ, Slotkin TA. β-Adrenoceptor modulation of transiently-overexpressed α_two-adrenoceptors in brain and peripheral tissues: mechanisms underlying the developmental toxicity of terbutaline. Encephalon Res Balderdash. 2004;62:305–xiv. [PubMed] [Google Scholar]
• Kudlacz EM, Navarro HA, Eylers JP, Lappi SE, Dobbins SS, Slotkin TA. Effects of prenatal terbutaline exposure on cellular development in lung and liver of neonatal rat: ornithine decarboxylase activeness and macromolecules. Pediatr Res. 1989;25:617–22. [PubMed] [Google Scholar]
• Lam F, Bergauer NK, Jacques D, Coleman SK, Stanziano GJ. Clinical and cost-effectiveness of continuous subcutaneous terbutaline versus oral tocolytics for treatment of recurrent preterm labor in twin gestations. J Perinatol. 2001;21:444–50. [PubMed] [Google Scholar]
• Lauder JM. Roles for neurotransmitters in development: possible interaction with drugs during the fetal and neonatal periods. In: Marois M, editor. Prevention of Concrete and Mental Congenital Defects. New York: Alan R. Liss; 1985. pp. 375–lxxx. [PubMed] [Google Scholar]
• McMillian MK, Schanberg SM, Kuhn CM. Ontogeny of rat hepatic adrenoceptors. J Pharmacol Exp Ther. 1983;227:181–6. [PubMed] [Google Scholar]
• Morris One thousand, Slotkin TA. Beta-2 adrenergic command of ornithine decarboxylase activity in brain regions of the developing rat. J Pharmacol Exp Ther. 1985;233:141–seven. [PubMed] [Google Scholar]
• Navarro HA, Kudlacz EM, Kavlock RJ, Slotkin TA. Prenatal terbutaline handling: tissue-selective dissociation of perinatal changes in β-adrenergic receptor bounden from regulation of adenylate cyclase action. Life Sci. 1991;48:269–74. [PubMed] [Google Scholar]
• Pitzer One thousand, Schmidt MH, Esser G, Laucht Chiliad. Child development subsequently maternal tocolysis with β-sympathomimetic drugs. Child Psychiat Hum Dev. 2001;31:165–82. [PubMed] [Google Scholar]
• Rhodes MC, Seidler FJ, Abdel-Rahman A, Tate CA, Nyska A, Rincavage HL, et al. Terbutaline is a developmental neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus and somatosensory cortex. J Pharmacol Exp Ther. 2004;308:529–37. [PubMed] [Google Scholar]
• Robinson BV, Ettedgui JA, Sherman FS. Utilize of terbutaline in the treatment of complete middle block in the fetus. Cardiol Immature. 2001;11:683–vi. [PubMed] [Google Scholar]
• Rodier PM. Structural-functional relationships in experimentally induced brain damage. Prog Encephalon Res. 1988;73:335–48. [PubMed] [Google Scholar]
• Sanders JD, Happe HK, Bylund DB, Murrin LC. Changes in postnatal norepinephrine modify α₂ adrenergic receptor development. Neuroscience. 2011;192:761–72. [PMC free article] [PubMed] [Google Scholar]
• Seidler FJ, Slotkin TA. Presynaptic and postsynaptic contributions to ontogeny of sympathetic control of heart rate in the preweanling rat. Br J Pharmacol. 1979;65:431–4. [PMC free article] [PubMed] [Google Scholar]
• Seidler FJ, Slotkin TA. Evolution of cardinal control of norepinephrine turnover and release in the rat heart: responses to tyramine, 2-deoxyglucose and hydralazine. Neuroscience. 1981;vi:2081–six. [PubMed] [Google Scholar]
• Shizukuda Y, Buttrick PM. Subtype specific roles of β-adrenergic receptors in apoptosis of adult rat ventricular myocytes. J Mol Cell Cardiol. 2002;34:823–31. [PubMed] [Google Scholar]
• Slotkin TA. Endocrine command of synaptic development in the sympathetic nervous system: the cardiac-sympathetic axis. In: Gootman PM, editor. Developmental Neurobiology of the Autonomic Nervous System. Clifton, NJ: Humana Printing; 1986. pp. 97–133. [Google Scholar]
• Slotkin TA, Auman JT, Seidler FJ. Ontogenesis of β-adrenoceptor signaling: implications for perinatal physiology and for fetal effects of tocolytic drugs. J Pharmacol Exp Ther. 2003;306:1–7. [PubMed] [Google Scholar]
• Slotkin TA, Baker FE, Dobbins SS, Eylers JP, Lappi SE, Seidler FJ. Prenatal terbutaline exposure in the rat: selective furnishings on development of noradrenergic projections to cerebellum. Brain Res Bull. 1989;23:263–5. [PubMed] [Google Scholar]
• Slotkin TA, Kavlock RJ, Cowdery T, Orband L, Bartolome M, Grayness JA, et al. Functional consequences of prenatal methylmercury exposure: effects on renal and hepatic responses to trophic stimuli and on renal excretory mechanisms. Toxicol Lett. 1986;34:231–45. [PubMed] [Google Scholar]
• Slotkin TA, Kudlacz EM, Lappi SE, Tayyeb MI, Seidler FJ. Fetal terbutaline exposure causes selective postnatal increases in cerebellar α-adrenergic receptor binding. Life Sci. 1990;47:2051–vii. [PubMed] [Google Scholar]
• Slotkin TA, Lorber BA, McCook EC, Barnes GA, Seidler FJ. Neural input and the development of adrenergic intracellular signaling: neonatal denervation evokes neither receptor upregulation nor persistent supersensitivity of adenylate cyclase. Dev Brain Res. 1995;88:17–29. [PubMed] [Google Scholar]
• Slotkin TA, Saleh JL, Zhang J, Seidler FJ. Ontogeny of β-adrenoceptor/adenylyl cyclase desensitization mechanisms: the role of neonatal innervation. Encephalon Res. 1996;742:317–28. [PubMed] [Google Scholar]
• Slotkin TA, Seidler FJ. Anomalous regulation of β-adrenoceptor signaling in brain regions of the newborn rat. Brain Res. 2006;1077:54–8. [PubMed] [Google Scholar]
• Slotkin TA, Tate CA, Cousins MM, Seidler FJ. β-Adrenoceptor signaling in the developing brain: sensitization or desensitization in response to terbutaline. Dev Brain Res. 2001;131:113–25. [PubMed] [Google Scholar]
• Slotkin TA, Tate CA, Cousins MM, Seidler FJ. Imbalances sally in cardiac autonomic jail cell signaling subsequently neonatal exposure to terbutaline or chlorpyrifos, alone or in combination. Dev Brain Res. 2005;260:219–30. [PubMed] [Google Scholar]
• Tegner K, Nilsson HT, Persson CGA, Persson K, Ryrfeldt Å. Elimination pathways of terbutaline. Eur J Resp Dis. 1984;65 (Suppl 134):93–100. [PubMed] [Google Scholar]
• Thai Fifty, Galluzzo JM, McCook EC, Seidler FJ, Slotkin TA. Atypical regulation of hepatic adenylyl cyclase and adrenergic receptors during a disquisitional developmental period: agonists evoke supersensitivity accompanied by failure of receptor downregulation. Pediatr Res. 1996;39:697–707. [PubMed] [Google Scholar]
• Thornton JG. Maintenance tocolysis. Br J Obstet Gynæacol. 2005;1:118–21. [PubMed] [Google Scholar]
• U.S. Food and Drug Assistants. [accessed xviii May 2012]; FDA Drug Safety Communication: New warnings against use of terbutaline to treat preterm labor. 2011 http://world wide web.fda.gov/drugs/drugsafety/ucm243539.htm.
• Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the encephalon of patients with autism. Ann Neurol. 2004;57:67–81. [PubMed] [Google Scholar]
• Whitaker-Azmitia PM. Function of serotonin and other neurotransmitter receptors in brain development: ground for developmental pharmacology. Pharmacol Rev. 1991;43:553–61. [PubMed] [Google Scholar]
• Witter F, Zimmerman A, Reichmann J, Connors S. In utero β_ii adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes. Am J Obstet Gynecol. 2009;201:553–9. [PubMed] [Google Scholar]
• Yan LZ, Herrmann Five, Hofer JK, Insel PA. β-Adrenergic receptor/army camp-mediated signaling and apoptosis of S49 lymphoma cells. Am J Physiol. 2000;279:C1665–C74. [PubMed] [Google Scholar]
• Zaugg Chiliad, Xu WM, Lucchinetti E, Shafiq SA, Jamali NZ, Siddiqui MAQ. β-Adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. Circulation. 2000;102:344–50. [PubMed] [Google Scholar]
• Zerrate MC, Pletnikov G, Connors SL, Vargas DL, Seidler FJ, Zimmerman AW, et al. Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism. J Pharmacol Exp Ther. 2007;322:xvi–22. [PubMed] [Google Scholar]

garciaberighbour.blogspot.com

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492522/

Share this post